Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
1-(2-Bromoethyl)-4-methoxybenzene → 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(4-methoxyphenethyl)-5,5-dimethylimidazolidine-2,4-dione
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | 1-(2-Bromoethyl)-4-methoxybenzene | HCID 84427 | — |
| 반응물 | 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-5,5-dimethylimidazolidine-2,4-dione | HCID 59524388 | — |
| 생성물 | 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(4-methoxyphenethyl)-5,5-dimethylimidazolidine-2,4-dione | HCID 53373640 | — |
반응 단계
Prepared as in Example 12-16 from 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-5,5-dimethylimidazolidine-2,4-dione (Example 12-16a) and 1-(2-bromoethyl)-4-methoxybenzene. MS 438 (MH+). The title compound was shown to inhibit hT2R08 bitter receptor and had an IC50 of 0.12 μM.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US08076491B2 |
| 출처 데이터셋 | uspto-grants-2011_12 |
| ORD ID | ord-5bd6d9db829f4a6890dba5a65d591510 |
| 출처 메모 | uspto-grants-2011_12 |